Vincerx Pharma (VINC) Competitors $0.21 +0.00 (+1.55%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VINC vs. EQ, AKTX, SNTI, CMMB, CLDI, INKT, ATHA, LSTA, LSB, and GOVXShould you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Equillium (EQ), Akari Therapeutics (AKTX), Senti Biosciences (SNTI), Chemomab Therapeutics (CMMB), Calidi Biotherapeutics (CLDI), MiNK Therapeutics (INKT), Athira Pharma (ATHA), Lisata Therapeutics (LSTA), Lakeshore Biopharma (LSB), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry. Vincerx Pharma vs. Equillium Akari Therapeutics Senti Biosciences Chemomab Therapeutics Calidi Biotherapeutics MiNK Therapeutics Athira Pharma Lisata Therapeutics Lakeshore Biopharma GeoVax Labs Equillium (NASDAQ:EQ) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations. Does the media favor EQ or VINC? In the previous week, Equillium's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score. Company Overall Sentiment Equillium Neutral Vincerx Pharma Neutral Do institutionals & insiders believe in EQ or VINC? 27.0% of Equillium shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 30.3% of Equillium shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, EQ or VINC? Equillium has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Is EQ or VINC more profitable? Vincerx Pharma has a net margin of 0.00% compared to Equillium's net margin of -10.05%. Equillium's return on equity of -20.68% beat Vincerx Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Equillium-10.05% -20.68% -10.77% Vincerx Pharma N/A -248.33%-132.73% Which has stronger earnings & valuation, EQ or VINC? Equillium has higher revenue and earnings than Vincerx Pharma. Equillium is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$45.91M0.47-$13.34M-$0.14-4.34Vincerx PharmaN/AN/A-$40.16M-$1.03-0.20 Do analysts rate EQ or VINC? Equillium currently has a consensus price target of $5.00, suggesting a potential upside of 722.37%. Vincerx Pharma has a consensus price target of $2.00, suggesting a potential upside of 852.38%. Given Vincerx Pharma's higher probable upside, analysts plainly believe Vincerx Pharma is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer EQ or VINC? Equillium received 15 more outperform votes than Vincerx Pharma when rated by MarketBeat users. Likewise, 83.72% of users gave Equillium an outperform vote while only 65.63% of users gave Vincerx Pharma an outperform vote. CompanyUnderperformOutperformEquilliumOutperform Votes3683.72% Underperform Votes716.28%Vincerx PharmaOutperform Votes2165.63% Underperform Votes1134.38% SummaryEquillium beats Vincerx Pharma on 9 of the 14 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get Vincerx Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VINC vs. The Competition Export to ExcelMetricVincerx PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.07M$6.57B$5.02B$9.08BDividend YieldN/A3.09%4.87%4.20%P/E Ratio-0.2010.55135.0817.16Price / SalesN/A194.011,120.30115.67Price / CashN/A57.1640.5837.88Price / Book0.405.104.754.78Net Income-$40.16M$151.51M$118.50M$225.60M7 Day Performance9.95%-2.13%-1.85%-1.21%1 Month Performance-17.97%-3.13%11.28%3.09%1 Year Performance-75.12%11.54%29.91%16.48% Vincerx Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VINCVincerx Pharma2.2572 of 5 stars$0.21+1.5%$2.00+852.4%-67.6%$7.07MN/A-0.2060Gap UpEQEquillium2.912 of 5 stars$0.70-0.7%$5.00+614.3%-16.5%$24.80M$45.91M-5.0440Gap DownAKTXAkari TherapeuticsN/A$0.98+0.5%N/A-67.2%$24.20MN/A0.009Analyst ForecastGap DownSNTISenti Biosciences2.3363 of 5 stars$5.18-7.0%$10.00+93.1%-5.2%$23.77M$2.56M-0.334News CoverageGap UpCMMBChemomab Therapeutics3.3189 of 5 stars$1.64+3.8%$7.33+347.2%+230.1%$23.55MN/A-1.5820Positive NewsCLDICalidi Biotherapeutics2.0382 of 5 stars$1.76-4.9%$16.67+847.0%N/A$23.02M$50,000.000.0041News CoverageINKTMiNK Therapeutics2.2319 of 5 stars$0.58-5.8%$6.50+1,020.7%-47.6%$22.94MN/A-1.4930Gap UpATHAAthira Pharma2.1022 of 5 stars$0.59+0.9%$13.83+2,244.6%-72.6%$22.82MN/A-0.2140LSTALisata Therapeutics1.8934 of 5 stars$2.70+4.7%$15.00+455.6%-5.4%$22.67MN/A-1.1030LSBLakeshore Biopharma0.7256 of 5 stars$2.43-2.4%N/AN/A$22.62M$80.82M0.00773News CoverageGap UpGOVXGeoVax Labs2.9414 of 5 stars$2.34-0.4%$14.20+506.8%-54.8%$22.08M$3.09M0.0017Analyst ForecastNews Coverage Related Companies and Tools Related Companies EQ Competitors AKTX Competitors SNTI Competitors CMMB Competitors CLDI Competitors INKT Competitors ATHA Competitors LSTA Competitors LSB Competitors GOVX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VINC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
